Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future
- Author
- MÜLLER, R. H1 ; JACOBS, C1 ; KAYSER, O1
[1] Freie Universität Berlin, Institut für Pharmazie, Pharmazeutische Technologie, Biopharmazie and Biotechnologie, Kelchstrasse 31, 12169 Berlin, Germany - Issue title
- Nanoparticulate systems for improved drug delivery
- Author (monograph)
- KAWASHIMA, Y (Editor)1
[1] Gifu Pharmaceutical University, 5-6-1, Mitahora Higashi, Gifu 502-8585, Japan - Source
Advanced drug delivery reviews. 2001, Vol 47, Num 1, pp 3-19 ; ref : 52 ref
- ISSN
- 0169-409X
- Scientific domain
- Pharmacology drugs
- Publisher
- Elsevier Science, Shannon
- Publication country
- Ireland
- Document type
- Article
- Language
- English
- Keyword (fr)
- Article synthèse Ciblage Forme pharmaceutique Homogénéisation Propriété physicochimique Solubilité Suspension colloïdale Système administration Technologie pharmaceutique Vecteur médicament Voie administration Voie orale Voie parentérale
- Keyword (en)
- Review Targeting Dosage form Homogenization Physicochemical properties Solubility Colloidal suspension Delivery system Pharmaceutical technology Drug carrier Route of administration Oral administration Parenteral administration
- Keyword (es)
- Artículo síntesis Blancado Forma farmacéutica Homogeneización Propiedad fisicoquímica Solubilidad Suspensión coloidal Sistema administración Tecnología farmacéutica Vector medicamento Vía administración Vía oral Vía parenteral
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02A General pharmacology / 002B02A03 Pharmaceutical technology. Pharmaceutical industry
- Discipline
- General pharmacology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 975909
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Install on your browser
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:124:\"Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future\";s:9:\"\u0000*\u0000jtitle\";s:30:\"Advanced drug delivery reviews\";s:9:\"\u0000*\u0000stitle\";s:20:\"Adv. drug deliv. rev\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"47\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:1:\"3\";s:8:\"\u0000*\u0000epage\";s:2:\"19\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0169-409X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"M\u00dcLLER\";s:10:\"\u0000*\u0000aufirst\";s:4:\"R. H\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:9:\"JACOBS, C\";i:1;s:9:\"KAYSER, O\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:50:\"Nanoparticulate systems for improved drug delivery\";s:8:\"\u0000*\u0000title\";s:124:\"Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future\";s:8:\"\u0000*\u0000place\";s:7:\"Shannon\";s:6:\"\u0000*\u0000pub\";s:16:\"Elsevier Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:124:\"Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future\";s:9:\"\u0000*\u0000jtitle\";s:30:\"Advanced drug delivery reviews\";s:9:\"\u0000*\u0000stitle\";s:20:\"Adv. drug deliv. rev\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"47\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:1:\"3\";s:8:\"\u0000*\u0000epage\";s:2:\"19\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0169-409X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"M\u00dcLLER\";s:10:\"\u0000*\u0000aufirst\";s:4:\"R. H\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:9:\"JACOBS, C\";i:1;s:9:\"KAYSER, O\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:50:\"Nanoparticulate systems for improved drug delivery\";s:8:\"\u0000*\u0000title\";s:124:\"Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future\";s:8:\"\u0000*\u0000place\";s:7:\"Shannon\";s:6:\"\u0000*\u0000pub\";s:16:\"Elsevier Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:124:\"Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future\";s:9:\"\u0000*\u0000jtitle\";s:30:\"Advanced drug delivery reviews\";s:9:\"\u0000*\u0000stitle\";s:20:\"Adv. drug deliv. rev\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"47\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:1:\"3\";s:8:\"\u0000*\u0000epage\";s:2:\"19\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0169-409X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"M\u00dcLLER\";s:10:\"\u0000*\u0000aufirst\";s:4:\"R. H\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:9:\"JACOBS, C\";i:1;s:9:\"KAYSER, O\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:50:\"Nanoparticulate systems for improved drug delivery\";s:8:\"\u0000*\u0000title\";s:124:\"Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future\";s:8:\"\u0000*\u0000place\";s:7:\"Shannon\";s:6:\"\u0000*\u0000pub\";s:16:\"Elsevier Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:124:\"Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future\";s:9:\"\u0000*\u0000jtitle\";s:30:\"Advanced drug delivery reviews\";s:9:\"\u0000*\u0000stitle\";s:20:\"Adv. drug deliv. rev\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"47\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:1:\"3\";s:8:\"\u0000*\u0000epage\";s:2:\"19\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0169-409X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"M\u00dcLLER\";s:10:\"\u0000*\u0000aufirst\";s:4:\"R. H\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:9:\"JACOBS, C\";i:1;s:9:\"KAYSER, O\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:50:\"Nanoparticulate systems for improved drug delivery\";s:8:\"\u0000*\u0000title\";s:124:\"Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future\";s:8:\"\u0000*\u0000place\";s:7:\"Shannon\";s:6:\"\u0000*\u0000pub\";s:16:\"Elsevier Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:124:\"Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future\";s:9:\"\u0000*\u0000jtitle\";s:30:\"Advanced drug delivery reviews\";s:9:\"\u0000*\u0000stitle\";s:20:\"Adv. drug deliv. rev\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"47\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:1:\"3\";s:8:\"\u0000*\u0000epage\";s:2:\"19\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0169-409X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"M\u00dcLLER\";s:10:\"\u0000*\u0000aufirst\";s:4:\"R. H\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:9:\"JACOBS, C\";i:1;s:9:\"KAYSER, O\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:50:\"Nanoparticulate systems for improved drug delivery\";s:8:\"\u0000*\u0000title\";s:124:\"Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future\";s:8:\"\u0000*\u0000place\";s:7:\"Shannon\";s:6:\"\u0000*\u0000pub\";s:16:\"Elsevier Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
